Biocon (NSE:BIOCON, BOM:532523) has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Program (PAP), according to an Indian bourse filing on Tuesday.
The program aims at improving access to affordable, high-quality biosimilars for underserved cancer patients, the filing said.
Under the initiative, Biocon will supply oncology biosimilars such as Trastuzumab, Pegfilgrastim, and Bevacizumab, while NCSM will manage patient enrolment and distribution.
The program will begin by offering Trastuzumab to patients experiencing treatment delays due to financial constraints.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.